Danaher Corporation (DHR) Position Increased by Van Hulzen Asset Management LLC
Van Hulzen Asset Management LLC increased its stake in Danaher Corporation (NYSE:DHR) by 322.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,747 shares of the conglomerate’s stock after purchasing an additional 42,543 shares during the period. Danaher accounts for about 1.6% of Van Hulzen Asset Management LLC’s portfolio, making the stock its 20th largest position. Van Hulzen Asset Management LLC’s holdings in Danaher were worth $4,782,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after buying an additional 520,776 shares during the last quarter. BlackRock Inc. raised its position in Danaher by 3.2% during the 2nd quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock worth $3,308,239,000 after buying an additional 1,233,876 shares during the last quarter. FMR LLC raised its position in Danaher by 0.9% during the 2nd quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock worth $1,656,100,000 after buying an additional 183,183 shares during the last quarter. Parnassus Investments CA raised its position in Danaher by 0.3% during the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after buying an additional 29,381 shares during the last quarter. Finally, Flossbach Von Storch AG raised its position in Danaher by 17.2% during the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after buying an additional 994,902 shares during the last quarter. Institutional investors own 76.28% of the company’s stock.
In other news, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the transaction, the director now directly owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 273,810 shares of company stock valued at $25,218,813. Insiders own 12.20% of the company’s stock.
A number of equities analysts have issued reports on the stock. Cowen reissued a “buy” rating and set a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. J P Morgan Chase & Co reissued an “overweight” rating and set a $95.00 price target on shares of Danaher in a research report on Friday, September 8th. Jefferies Group reissued a “buy” rating and set a $95.00 price target on shares of Danaher in a research report on Friday, August 4th. Robert W. Baird raised their price target on shares of Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Danaher has an average rating of “Buy” and a consensus price target of $93.31.
Danaher Corporation (NYSE:DHR) traded down $0.53 during trading hours on Friday, hitting $93.82. 2,310,000 shares of the stock traded hands, compared to its average volume of 2,400,000. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The stock has a market cap of $65,260.00, a price-to-earnings ratio of 24.25, a price-to-earnings-growth ratio of 2.24 and a beta of 1.02. Danaher Corporation has a 52-week low of $76.27 and a 52-week high of $94.82.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 EPS. equities research analysts forecast that Danaher Corporation will post 3.99 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/01/danaher-corporation-dhr-position-increased-by-van-hulzen-asset-management-llc.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.